Company News
Roivant Shares Jump 17% on Mosliciguat Success
Roivant Sciences' experimental drug mosliciguat met primary endpoints in a 135‑patient mid‑stage trial for pulmonary hypertension linked to interstitial lung disease.
The study reported a 56.3% drop i
